Search the Studies

29 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001032-CBAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (Recruitment has not started18-125 YearsNCI Pancreatic
000958-CProspective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by Invitation18-125 YearsNCI Pancreatic
000954-CA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing CancerParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
000930-CA Phase 1b/2 Study of HCW9218, a Bifunctional TGF-Beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic CancerParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
000596-CPhase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
000567-CPhase 1 Trial of Gemcitabine Combined with the BAY 1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian CancerParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
000494-DKNatural History of Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity AssessmentParticipants currently recruited/enrolled18-125 YearsNIDDKPancreatic
000254-CA Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)Participants currently recruited/enrolled18-125 YearsNCI Pancreatic
000194-CA Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
20-C-0023First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsParticipants currently recruited/enrolled12-125 YearsNCI Pancreatic
20-C-0013Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Pancreatic
19-C-0135Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsParticipants currently recruited/enrolled12-125 YearsNCI Pancreatic
19-C-0128A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
19-C-0039Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
19-C-0033Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic CancersCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
19-C-0017A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-70 YearsNCI Pancreatic
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Pancreatic
18-C-0147Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
17-C-0113A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-70 YearsNCI Pancreatic
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersParticipants currently recruited/enrolled18-70 YearsNCI Pancreatic
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI Pancreatic
12-C-0175Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic TargetsCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
11-C-0112Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal CancerParticipants currently recruited/enrolled18-125 YearsNCI Pancreatic
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabParticipants currently recruited/enrolled18-72 YearsNCI Pancreatic
08-H-0186Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with BortezomibCompleted Study; data analyses ongoing18-70 YearsNHLBIPancreatic
04-C-0238A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Pancreatic
87-DK-0029Diagnosis and Treatment of Patients with Cystic FibrosisParticipants currently recruited/enrolled4-125 YearsNIDDKPancreatic
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®